好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Rare Case of Primary Dural Based Marginal Zone B-Cell Lymphoma Camouflaging as Mild Focal Dura Thickness and Pachymeningeal Enhancement
Neuro-oncology
Neuro-oncology Posters (7:00 AM-5:00 PM)
043
To highlight the importance of surveillance for patients with mild focal pachymeningeal enhancement and biopsy if no radiographic resolution has been seen on imaging as these findings could represent rare malignancy such as MZBCL.

Primary Dural Based Marginal Zone B-Cell Lymphoma (MZBCL) is a subtype of PCNSL with an incidence rate ranging from 0.6 to 3% of all brain tumors. MZBCL typically presents as an extra-axial mass resembling meningioma.

Here we report an unusual case of MZBCL with an initial radiographic findings of mild nonspecific thickening of tentorium and pachymeningeal enhancement surrounding 7th/8th cranial nerves.

Case Study 

A 58-year old right-handed woman with clinical history of CMV infection, polyclonal gammopathy and unruptured left ICA aneurysm post coil embolization who presented for an evaluation of mild thickening, and enhancement of the left tentorium cerebelli and 7th/8th nerve root complex.

Differential considerations included inflammatory/autoimmune conditions (idiopathic hypertrophic pachymeningitis, neurosarcoidosis, Tolosa-Hunt syndrome), infections, structural lesion, benign or malignant neoplasm. Serum studies were normal. CSF studies were unremarkable. Flow cytometry showed no malignant cells with few small lymphocytes.

She was followed with the imaging surveillance for nine months until further increased thickening of dura on MRI. She underwent cerebellar dural biopsy that was consistent with MZBCL composed mainly of small CD20+ B-cells and negative MYD88. PET scan did not show any CNS, meningeal or systemic FDG involvement. Bone biopsy revealed no evidence of lymphoma. The focal leptomeningeal enhancement improved significantly after she received four doses of systemic rituximab treatment.

Our case highlights the importance of surveillance and brain biopsy in cases of mild focal dura/pachymeningeal thickness and enhancement if no conclusive diagnosis has been established, as it might be one of the rare tumors such as MZBCL.
Authors/Disclosures
Maya Hrachova, DO (Home)
PRESENTER
Dr. Hrachova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks Therapeutics.
Xiao-Tang Kong, MD, PhD (UC Irvine) Dr. Kong has nothing to disclose.